Gujarat pharma market rebounds to double-digit growth in 2024

Ahmedabad:  Gujarat’s pharmaceutical sector is back in the spotlight, ending 2024 on a high note with double-digit growth for the first time in three years. With Rs 9,855 crore in moving annual total (MAT) sales — 10.08% increase from Rs 8,952 crore in Dec 2023, the industry has not only bounced back from post-pandemic challenges but has also aligned itself with the national growth trajectory.

The sector’s rebound has been driven by several factors, including enhanced healthcare investments, increased demand for pharmaceutical products and a revival in export activities. Sheetal Sapale, vice-president (commercial), Pharmarack, said, “The growth is pretty much in line with the India growth, which grew at 8% during the year. Cardiac, anti-infectives and anti-diabetic therapies accounted for the maximum sales in India.”

New product launches and price factors are among other reasons driving the market’s growth. Viranchi Shah, national president of the Indian Drug Manufacturers’ Association (IDMA), said, “The recovery in Gujarat’s pharmaceutical market is a positive sign for the industry. One of the key factors has been the gradual return of post-Covid patients to clinics, contributing to an improvement in patient count. Increased govt initiatives, such as broader insurance coverage, have also played a vital role in driving accessibility and growth.”

He added, “The rise in sales volumes of off-patented drugs, coupled with the growing market for cardiovascular, metabolic and cancer therapies, highlights shifting incidences of ailments and healthcare priorities. New product launches and value growth from price adjustments are further bolstering the sector. Looking ahead, the double-digit growth trend seems set to continue, underscoring a promising outlook for the pharmaceutical industry.”

Related Posts

  • Pharma
  • February 17, 2025
  • 74 views
GSK Pharma shares gain 20% following strong Q3FY25 results

GSK Pharma shares gained by 20 percent on Monday, February 17, as brokerages like ICICI Securities and Motilal Oswal continue to maintain positive rating of the stock. GlaxoSmithKline Pharmaceuticals Ltd…

  • Pharma
  • February 17, 2025
  • 70 views
Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

Shares of Glenmark Pharmaceuticals Ltd rose 4% on February 17 after the firm gave a strong guidance for FY26 and it returned to black in the December quarter. The drugmaker…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Wow! What a Change of Heart in Practitioners of Allopathy!

Wow! What a Change of Heart in Practitioners of Allopathy!

GSK Pharma shares gain 20% following strong Q3FY25 results

GSK Pharma shares gain 20% following strong Q3FY25 results

Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

US Tariffs on pharma: What are the potential impact on Indian drugmakers

US Tariffs on pharma: What are the potential impact on Indian drugmakers

Twin Health bats a1000 before enters Digital Health NY 100

Twin Health bats a1000 before enters Digital Health NY 100

US tariff jitters rock pharma stocks; Sun Pharma, Lupin, Dr Reddy’s slump 2-4%

US tariff jitters rock pharma stocks; Sun Pharma, Lupin, Dr Reddy’s slump 2-4%